Neuroproteases in peptide neurotransmission and neurodegenerative diseases: applications to drug discovery research

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
V Y Hook

Abstract

The nervous system represents a key area for development of novel therapeutic agents for the treatment of neurological and neurodegenerative diseases. Recent research has demonstrated the critical importance of neuroproteases for the production of specific peptide neurotransmitters and for the production of toxic peptides in major neurodegenerative diseases that include Alzheimer, Huntington, and Parkinson diseases. This review illustrates the successful criteria that have allowed identification of proteases responsible for converting protein precursors into active peptide neurotransmitters, consisting of dual cysteine protease and subtilisin-like protease pathways in neuroendocrine cells. These peptide neurotransmitters are critical regulators of neurologic conditions, including analgesia and cognition, and numerous behaviors. Importantly, protease pathways also represent prominent mechanisms in neurodegenerative diseases, especially Alzheimer, Huntington, and Parkinson diseases. Recent studies have identified secretory vesicle cathepsin B as a novel beta-secretase for production of the neurotoxic beta-amyloid (Abeta) peptide of Alzheimer disease. Moreover, inhibition of cathepsin B reduces Abeta peptide levels in brain. These...Continue Reading

References

Dec 1, 1992·Archives of Biochemistry and Biophysics·D J ButtleA J Barrett
Mar 1, 1991·Trends in Pharmacological Sciences·P WalkerB Waeber
Sep 26, 1995·Proceedings of the National Academy of Sciences of the United States of America·M YoshimotoT Saitoh
Oct 1, 1995·The Biochemical Journal·L L IversenM S Shearman
Dec 1, 1994·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·V Y HookN Tezapsidis
Dec 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·K UédaT Saitoh
Jun 1, 1995·Clinical and Experimental Pharmacology & Physiology·R Kanjhan
Jun 24, 1997·Proceedings of the National Academy of Sciences of the United States of America·M FurutaD F Steiner
Jan 1, 1997·Human Molecular Genetics·G P BatesS W Davies
May 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·J DeussingJ A Villadangos
May 8, 1998·Seminars in Cell & Developmental Biology·K GensbergG M Matthews
May 22, 1998·Journal of Neuropathology and Experimental Neurology·J P Vonsattel, M DiFiglia
May 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·M G SpillantiniM Goedert
Jul 17, 1998·Current Opinion in Chemical Biology·D F Steiner
Sep 16, 1998·Human Genetics·C LavedanM H Polymeropoulos
Oct 30, 1998·Molecular Medicine Today·O RiessR Krüger
Jul 20, 1999·The Journal of Biological Chemistry·A ZhouD F Steiner
Nov 5, 1999·The Journal of Clinical Investigation·S S Sisodia
Nov 24, 1999·Molecular and Cellular Neurosciences·I HussainG Christie
Mar 4, 2000·Proceedings of the National Academy of Sciences of the United States of America·X LinJ Tang
Mar 10, 2000·Biochimica Et Biophysica Acta·B TurkV Turk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.